Bills · H.R. 10857 · Text

Introduced in House

Confirmed from the official record

Our copy of the file on govinfo.gov, saved November 13, 2026. Fingerprint (SHA-256): 8c4409ad7c8c4538.

H.R. 10857: the bill

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 10857 Introduced in House (IH)]

<DOC>






119th CONGRESS
  2d Session
                               H. R. 10857

To amend the Federal Food, Drug, and Cosmetic Act and the Public Health 
 Service Act to advance the next-generation of clinical development of 
          novel treatments and cures, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            October 22, 2026

Mr. Auchincloss (for himself and Mr. Griffith) introduced the following 
 bill; which was referred to the Committee on Energy and Commerce, and 
  in addition to the Committee on Ways and Means, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL


 
To amend the Federal Food, Drug, and Cosmetic Act and the Public Health 
 Service Act to advance the next-generation of clinical development of 
          novel treatments and cures, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE; TABLE OF CONTENTS.

    (a) Short Title.--This Act may be cited as the ``Faster Clinical 
Trials Act''.
    (b) Table of Contents.--The table of contents for this Act is as 
follows:

Sec. 1. Short title; table of contents.
       TITLE I--EMBEDDING CLINICAL STUDIES IN ROUTINE HEALTH CARE

Sec. 101. Cures in Care Initiative.
Sec. 102. Cures in Care Initiative lead network grant program.
Sec. 103. Cures in Care Initiative Collaborative.
Sec. 104. Definitions for Cures in Care Initiative and related 
                            activities.
Sec. 105. Data standards with respect to data sharing.
Sec. 106. Clinical trial oversight modernization.
Sec. 107. Updates to patient costs and payment for participation in 
                            clinical trials.
 TITLE II--MODERNIZED PRECLINICAL AND EARLY-STAGE CLINICAL DEVELOPMENT

Sec. 201. Modernized evidence generation through new approach 
                            methodologies.
Sec. 202. Modernized phase 1 clinical trial oversight.
Sec. 203. Global regulatory alignment to modernize clinical 
                            development.
Sec. 204. Minimum United States representation in clinical trials.
Sec. 205. Food and Drug Administration Rare Disease Innovation Hub.
TITLE III--ENHANCED FOOD AND DRUG ADMINISTRATION REGULATIONS TO SUPPORT 
                               INNOVATION

Sec. 301. Resolving clinical holds and improving clinical trial 
                            efficiency.
Sec. 302. Mutual recognition of GMP standards.
Sec. 303. Pathway for competitive generic therapies.
Sec. 304. Biosimilar biological products.
Sec. 305. Certification of patent information in certain applications 
                            for biological products.
Sec. 306. GAO report.
Sec. 307. Definitions.
               TITLE IV--PRECISION ONCOLOGY MODERNIZATION

Sec. 401. Findings and purpose.
Sec. 402. Oncology Center of Excellence.
Sec. 403. Labeling revisions for genomic exclusions in oncology drugs.
                   TITLE V--AMERICAN FRONTIER BIOBANK

Sec. 501. Establishment of the American Frontier Biobank.

       TITLE I--EMBEDDING CLINICAL STUDIES IN ROUTINE HEALTH CARE

SEC. 101. CURES IN CARE INITIATIVE.

    (a) In General.--Part J of title IV of the Public Health Service 
Act (42 U.S.C. 290c et seq.) is amended by adding at the end the 
following:

``SEC. 499B. CURES IN CARE INITIATIVE ESTABLISHMENT.

    ``(a) Center for Clinical Trial Innovation.--The Secretary shall 
establish the Center for Clinical Trial Innovation (in this section 
referred to as the `Center') within the Center for Drug Evaluation and 
Research of the Food and Drug Administration to carry out the 
Initiative established under subsection (b), to be headed by a 
director.
    ``(b) Establishment of Cures in Care Initiative.--
            ``(1) In general.--The Secretary, acting through the 
        Assistant Secretary of Health shall continue a Cures in Care 
        Initiative (in this section referred to as the `Initiative') to 
        expand, enhance, and promote routine point-of-care clinical 
        trials, including through the establishment and support of 
        broad-based clinical trial networks (in this section referred 
        to as a `lead network'), for the purpose of accelerating the 
        development of new treatments and cures by generating clinical 
        evidence faster and through novel methods.
            ``(2) Coordination and implementation.--The Assistant 
        Secretary of Health shall coordinate the activities of the 
        Commissioner of Food and Drugs and the Director of the National 
        Institutes of Health in implementing the Initiative.
            ``(3) Principal office.--The Secretary shall establish the 
        Center for Clinical Trial Innovation (in this section referred 
        to as the `Center') within the Center for Drug Evaluation and 
        Research of the Food and Drug Administration to serve as the 
        principal implementing office supporting the Assistant 
        Secretary of Health in carrying out the Initiative established 
        under subsection (a), to be headed by a director.
    ``(c) Duties.--In carrying out the Initiative, the Director shall--
            ``(1) identify priority disease or mechanism areas for the 
        purpose of implementing lead networks;
            ``(2) establish lead networks for each such a priority 
        disease or mechanism area by building on existing clinical 
        trial networks and infrastructures;
            ``(3) ensure each such network prioritizes the 
        participation of less-resourced clinical trial settings;
            ``(4) ensure each such network focuses on not less than--
                    ``(A) 1 high-burden chronic disease; and
                    ``(B) 1 group of rare diseases that are related or 
                similar to each other;
            ``(5) designate a central institutional review board to 
        review any routine point-of-care clinical trial carried out by 
        a lead network pursuant to this subsection;
            ``(6) coordinate actions carried out under the Initiative 
        for purposes of addressing barriers to the conduct of routine 
        point-of-care clinical trials carried out by a lead network 
        pursuant to this subsection, with respect to--
                    ``(A) shared or central institutional review board 
                oversight;
                    ``(B) patient consent, including electronic 
                consent;
                    ``(C) alignment of health information technology 
                interoperability standards adopted by the Office of the 
                National Coordinator for Health Information Technology, 
                program data requirements administered by the Centers 
                for Medicare & Medicaid Services and the real-world 
                data standards maintained by the Commissioner of Food 
                and Drugs, consistent with applicable privacy and 
                confidentiality protections;
                    ``(D) development of innovative clinical trial 
                methods;
                    ``(E) publication transparency and reproducibility;
                    ``(F) digital tools and artificial intelligence to 
                reduce the cost and burden of such clinical trials;
                    ``(G) necessary infrastructure to implement a 
                decentralized clinical trial network, in a hub-and-
                spoke model; and
                    ``(H) governance of such clinical trials at 
                multiple sites;
            ``(7) establish an Food and Drug Administration-endorsed 
        clinical trial site certification program; and
            ``(8) in consultation with the Director of the National 
        Center for Advancing Translational Sciences award grants and 
        enter into contracts, cooperative agreements, and other 
        transactions, including as authorized under sections 499A(g) 
        and 499C.
    ``(d) Rapid Implementation.--The Director shall--
            ``(1) establish not less than 3 lead networks under 
        subsection (c) not later than 1 year after the date of 
        enactment of this subsection; and
            ``(2) upon establishment of such lead networks, develop the 
        plan described in subsection (e).
    ``(e) Implementation Plan for Expanding Activities.--
            ``(1) In general.--Not later than 3 years after the date of 
        enactment of this subsection, the Director shall implement a 
        comprehensive implementation plan describing how the Initiative 
        will broadly extend covered activities to the public and 
        private development of medical products, including stretch 
        goals with timeframes for--
                    ``(A) achieving expanded patient access and site 
                access to routine point-of-care clinical trials, 
                including ensuring patient access at 60 percent of 
                health care delivery sites and for 90 percent of 
                eligible patients that participate in a clinical trial 
                carried out by a lead network established under 
                subsection (c);
                    ``(B) reducing the cost of such a clinical trial, 
                including approaching a 30 to 50 percent reduction in 
                cost per patient and a 30 percent reduction in accrual 
                time;
                    ``(C) enhancing any impact of such a clinical 
                trial, including ensuring that 90 percent of patients 
                participating in such a clinical trial obtain a timely, 
                independently reviewed, and publicly reported result; 
                and
                    ``(D) assessing if lead networks are improving 
                trial execution, including site activation timelines, 
                time to first patient enrolled, enrollment and 
                retention performance, data quality, monitoring burden, 
                technology and workflow readiness, and the long-term 
                research readiness of participating sites.
            ``(2) Publication.--Not later than 3 years after the date 
        of enactment of this paragraph, the Director shall make 
        available to the public on the website of the Department of 
        Health and Human Services the implementation plan implemented 
        under paragraph (1).
            ``(3) Covered activity defined.--For purposes of paragraph 
        (1), the term `covered activity' means--
                    ``(A) identifying priority disease or mechanism 
                areas under subsection (c) for the purpose of 
                implementing broad-based point-of-care clinical trial 
                networks; or
                    ``(B) establishing a lead network under such 
                subsection for each such priority disease or mechanism 
                area.
    ``(f) Collaboration and Consultation.--
            ``(1) Required collaboration and consultation.--In carrying 
        out the Initiative, the Director shall collaborate and consult 
        with--
                    ``(A) the Administrator of the Centers for Medicare 
                & Medicaid Services;
                    ``(B) the Director of the Advanced Research 
                Projects Agency-Health;
                    ``(C) the Administrator of the Health Resources and 
                Services Administration;
                    ``(D) the Office of the National Coordinator for 
                Health Information Technology;
                    ``(E) the Director of the Center for Biologics 
                Evaluation and Research;
                    ``(F) the Office of the Assistant Secretary of 
                Health; and
                    ``(G) representatives from--
                            ``(i) health care organizations in a lead 
                        network;
                            ``(ii) network users, including researchers 
                        and clinical trial administrators;
                            ``(iii) provider groups that do not 
                        directly collaborate with lead networks, 
                        including health systems, academic medical 
                        centers, and specialty medical societies;
                            ``(iv) private and nonprofit organizations 
                        funding such organizations and groups;
                            ``(v) patient advocacy organizations;
                            ``(vi) contract research organizations;
                            ``(vii) technology partners; and
                            ``(viii) such other partner organizations 
                        as the Director determines appropriate.
            ``(2) Additional collaboration and consultation.--In 
        addition to the collaboration and consultation required under 
        paragraph (1), the Director may, as appropriate, collaborate 
        and consult with--
                    ``(A) the Secretary of Veterans Affairs; and
                    ``(B) the Secretary of Defense, including the 
                Director of the Defense Health Agency.
    ``(g) Training and Technical Assistance.--
            ``(1) In general.--In carrying out the Initiative, the 
        Director, in consultation with the Director of the National 
        Center for Advancing Translational Sciences, shall provide 
        training and technical assistance to--
                    ``(A) a lead network established under subsection 
                (c);
                    ``(B) a health care organization or other partner 
                organization seeking to participate in a routine point-
                of-care clinical trial carried out by a lead network;
                    ``(C) any entity that applies for a grant, 
                cooperative agreement, contract, or other transaction 
                under section 499C but does not receive such grant, 
                cooperative agreement, contract, or other transaction; 
                and
                    ``(D) an emerging biotechnology company.
            ``(2) Contents.--In providing training and technical 
        assistance under paragraph (1), the Director may address 
        clinical development and regulatory subjects, including--
                    ``(A) protocol development;
                    ``(B) regulatory interactions with the Food and 
                Drug Administration;
                    ``(C) data infrastructure integration;
                    ``(D) sponsor and site engagement in designing, 
                conducting, and evaluating clinical trials;
                    ``(E) sustainability planning; and
                    ``(F) general public education on clinical trials 
                and their potential risks and benefits.
            ``(3) Format.--The Director shall make these training and 
        technical assistance materials available in an online resource 
        center, including resources on--
                    ``(A) staff training materials;
                    ``(B) trial-network participation;
                    ``(C) technology support;
                    ``(D) data quality assessments;
                    ``(E) Institutional Review Board templates and best 
                practices;
                    ``(F) study startup; and
                    ``(G) capacity building.
            ``(4) Priority.--In carrying out this subsection, the 
        Director shall give priority to less-resourced clinical trial 
        settings.
            ``(5) Contracts and cooperative agreements for training.--
        The Director may enter into contracts or cooperative agreements 
        with entities, such as the Reagan-Udall Foundation for the Food 
        and Drug Administration established under section 770 of the 
        Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379dd), to--
                    ``(A) establish training programs; and
                    ``(B) hold meetings for health care organizations, 
                clinical research organizations, technology partners, 
                and patient-led organizations participating in a lead 
                network established under subsection (c).
    ``(h) External Engagement.--The Commissioner of Food and Drugs 
shall establish and expand the external engagement capacity of the 
Center through the performance commitments under section 736B of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379h-2).
    ``(i) FDA Guidance.--Not later than 18 months after the date of 
enactment of this subsection, the Commissioner of Food and Drugs shall, 
in consultation with the Director, issue any draft or final guidance as 
may be necessary to carry out this section, including with respect to--
            ``(1) guidelines for carrying out routine point-of-care 
        clinical trial networks, including governance, data monitoring, 
        and application of an innovative clinical trial method, drawing 
        on existing Food and Drug Administration guidance for platform 
        studies;
            ``(2) any update to guidance on decentralized clinical 
        trials, remote monitoring of such trials, and real-world data 
        and real-world evidence; and
            ``(3) reliance on central institutional review boards and 
        electronic consent in routine point-of-care clinical trials.
    ``(j) Reports.--
            ``(1) Annual reports.--Not later than 1 year after the date 
        of enactment of this paragraph, and annually thereafter, the 
        Director shall submit to the Committee on Energy and Commerce 
        of the House of Representatives and the Committee on Health, 
        Education, Labor, and Pensions of the Senate, and make 
        available to the public on the website of the Department, a 
        report on, with respect to the period covered by the report, 
        the progress of the Initiative in advancing routine point-of-
        care clinical trials, with respect to each priority disease or 
        mechanism area and lead network established under subsection 
        (c), including--
                    ``(A) progress addressing any barrier described in 
                such subsection;
                    ``(B) the availability and performance of any 
                routine point-of-care clinical trial in the United 
                States;
                    ``(C) any trend in the United States with respect 
                to such clinical trials; and
                    ``(D) the participation rate of less-resourced 
                clinical trial settings in each such lead network.
            ``(2) Evaluation reports.--
                    ``(A) 3-year report.--Not later than 3 years after 
                the date of enactment of this subparagraph, the 
                Director shall submit to the Committee on Energy and 
                Commerce of the House of Representatives and the 
                Committee on Health, Education, Labor, and Pensions of 
                the Senate a report containing--
                            ``(i) an evaluation of--
                                    ``(I) the outcome of any 
                                coordination, collaboration, and 
                                consultation required under this 
                                section, including the performance of 
                                each lead network established under 
                                subsection (c);
                                    ``(II) any expanded patient access 
                                and site access to routine point-of-
                                care clinical trials that is 
                                attributable to the Initiative;
                                    ``(III) any improvement in the 
                                participation rate of less-resourced 
                                clinical trial settings that is 
                                attributable to the Initiative;
                                    ``(IV) any improvement in the 
                                participation rate of emerging 
                                biotechnology sponsors within the lead 
                                network; and
                                    ``(V) alignment of interagency 
                                action under this section; and
                            ``(ii) any recommendation for additional 
                        legislative action to accelerate progress in 
                        carrying out routine point-of-care clinical 
                        trials and developing medical products.
                    ``(B) 5-year report.--Not later than 5 years after 
                the date of enactment of this subparagraph, the 
                Director shall submit a report in such manner and 
                containing such information as required under 
                subparagraph (A).
    ``(k) Medical Product Defined.--In this section, the term `medical 
product' means--
            ``(1) a drug or device, as defined in section 201 of the 
        Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321); or
            ``(2) a biological product, as defined in section 351 of 
        this Act.
    ``(l) Authorization of Appropriations.--In addition to any funds 
made available in the FDA Innovation Account under section 
1002(b)(2)(A) of the 21st Century Cures Act (Public Law 114-255) and 
any amount made available under section 499C, there is authorized to be 
appropriated to carry out this section $500,000,000 for each of fiscal 
years 2027 through 2031, to remain available until expended.''.
    (b) FDA Innovation Account.--
            (1) Transfer of direct spending savings.--Section 
        1002(b)(2)(A) of the 21st Century Cures Act (Public Law 114-
        255) is amended to read as follows:
                    ``(A) In general.--The following amounts shall be 
                transferred to the Account from the general fund of the 
                Treasury:
                            ``(i) For fiscal year 2027, $20,000,000.
                            ``(ii) For fiscal year 2028, $60,000,000.
                            ``(iii) For fiscal year 2029, $70,000,000.
                            ``(iv) For fiscal year 2030, $75,000,000.
                            ``(v) For fiscal year 2031, $70,000,000.''.
            (2) Authorization of appropriations.--Section 1002(b)(3) of 
        the 21st Century Cures Act (Public Law 114-255) is amended by 
        striking ``2017 through 2025'' each place such term appears and 
        inserting ``2027 through 2031''.
            (3) FDA activities.--Section 1002(b)(4) of the 21st Century 
        Cures Act (Public Law 114-255) is amended to read as follows:
            ``(4) FDA activities.--The activities authorized to be 
        funded under this section are the activities under--
                    ``(A) section 507 of the Federal Food, Drug, and 
                Cosmetic Act (21 U.S.C. 357);
                    ``(B) section 1014 of such Act (21 U.S.C. 399g); 
                and
                    ``(C) section 499B of the Public Health Service 
                Act, as added by section 101(a) of the Faster Clinical 
                Trials Act.''.
    (c) Conforming Amendment.--Part J of Title IV of the Public Health 
Service (42 U.S.C. 290c et seq.) is further amended by striking 
``advanced research projects agency-health'' in the part heading and 
inserting ``advanced health research projects''.

SEC. 102. CURES IN CARE INITIATIVE LEAD NETWORK GRANT PROGRAM.

    Part J of title IV of the Public Health Service Act (42 U.S.C. 290c 
et seq.) is amended by adding at the end the following:

``SEC. 499C. CURES IN CARE INITIATIVE LEAD NETWORK GRANT PROGRAM.

    ``(a) In General.--Not later than 5 years after the date of 
enactment of this subsection, the Commissioner of Food and Drugs, in 
consultation with the Director of the Center for Clinical Trial 
Innovation, and the Director of the National Institutes of Health, 
acting through the Center for Advancing Translational Sciences and the 
Advanced Research Projects Agency-Health, (in this section referred to 
as the `Commissioner and Director') shall make grants to, or enter into 
cooperative agreements, contracts, or other transactions with, not 
fewer than 3 lead networks established under section 499B(c) to--
            ``(1) achieve not later than 3 years after the date on 
        which an appropriation is first made under subsection (e), 
        measurable improvements in the clinical evidence base for each 
        priority disease or mechanism area for which such network was 
        established; and
            ``(2) enable broader implementation of routine point-of-
        care clinical trials beyond such lead network.
    ``(b) Use of Funds.--The Commissioner and Director may require a 
lead network that receives a grant, or enters into a cooperative 
agreement, contract, or other transaction, under this section to use 
any funding received through such grant, cooperative agreement, 
contract, or transaction to--
            ``(1) implement the data sharing standards described under 
        section 105 of the Faster Clinical Trials Act;
            ``(2) implement site data infrastructure and clinical 
        research technology;
            ``(3) leverage existing clinical trial networks, Federal 
        digital health and artificial intelligence initiatives, and 
        virtual participation options, consistent with good clinical 
        practice;
            ``(4) provide a plan for reliable collection and sharing of 
        data on covariates, treatments, outcomes, and adverse events 
        with respect to the applicable disease or mechanism area;
            ``(5) support, as appropriate--
                    ``(A) phase 2 and 3 clinical trials;
                    ``(B) label expansion studies;
                    ``(C) comparative effectiveness studies; and
                    ``(D) post-market commitments and phase 4 
                commitments;
            ``(6) include sites and patients from less-resourced 
        clinical trial settings;
            ``(7) include patients from populations not primarily 
        served by academic health centers;
            ``(8) include emerging biotechnology companies;
            ``(9) establish grants specifically for less-resourced 
        sites, including federally qualified health centers, to enable 
        participation;
            ``(10) collaborate or partner with multiple commercial 
        developers of medical products (as defined in section 499B) 
        that are active in the applicable disease or mechanism area; 
        and
            ``(11) include a plan for sustainability with respect to a 
        routine point-of-care clinical trial carried out by such 
        platform, including a description of--
                    ``(A) any partial startup funding from a non-
                Federal source;
                    ``(B) an additional study on the common trial 
                platform to be carried out after the date on which the 
                period described in subsection (c) ends; and
                    ``(C) an understanding of how lead networks will 
                maintain infrastructure and research beyond initial 
                Federal support, including long-term site readiness, 
                staffing and workforce support, technology maintenance, 
                continued community-site participation, sponsor 
                adoption and utilization, and the operational resources 
                necessary to support multiple studies over time.
    ``(c) Duration.--
            ``(1) In general.--Subject to paragraph (2), a grant, 
        cooperation agreement, contract, or other transaction under 
        this section shall be for a period of not more than 5 years.
            ``(2) Extension for material contribution.--The 
        Commissioner and Director may extend the 5-year period 
        described in paragraph (1) by not more than 3 years if the 
        Commissioner and Director determine that such extension will 
        materially contribute to fulfillment of the implementation plan 
        required under section 499B.
    ``(d) Evaluation.--
            ``(1) In general.--The Cures in Care Initiative 
        Collaborative established under section 499D shall evaluate any 
        activity carried out using any funds received through a grant, 
        cooperative agreement, contract, or transaction under this 
        section, including--
                    ``(A) a partnership between a lead network and a 
                sponsor or health care organization that are additional 
                sites of care;
                    ``(B) compared to traditional baselines, the cost 
                of--
                            ``(i) recruiting, enrolling, and treating 
                        each patient enrolled in a routine point-of-
                        care clinical trial; and
                            ``(ii) completing each such trial;
                    ``(C) any research impact such an activity has on--
                            ``(i) such clinical trials;
                            ``(ii) any site in which such a clinical 
                        trial is performed; and
                            ``(iii) any effect on the evidence base;
                    ``(D) inclusion of less-resourced clinical trial 
                settings; and
                    ``(E) any opportunity to increase scaling and 
                sustainability with respect to such a clinical trial 
                carried out by a lead network that receives such funds, 
                including--
                            ``(i) a maintenance plan for clinical trial 
                        sites to continue participating after the 
                        initial grant period ends; and
                            ``(ii) continued education for sites and 
                        training opportunities for staff.
            ``(2) Publication.--Not later than 3 years after the date 
        of enactment of this paragraph, and annually thereafter, the 
        Collaborative shall make available to the public on the website 
        of the Department of Health and Human Services the evaluation 
        carried out under paragraph (1).
    ``(e) Budget Clarification; Agency Contributions.--
            ``(1) Authorization of appropriations.--There is authorized 
        to be appropriated to carry out this section such sums as 
        necessary for each of fiscal years 2027 through 2031, to remain 
        available until expended.
            ``(2) Common fund.--The Commissioner and Director may 
        reserve to carry out this section any amounts made available 
        under paragraph (1) for the Common Fund established under 
        section 402A(c)(1).
            ``(3) Budget clarification.--Any budget request of the 
        President shall specify an amount for carrying out this 
        section.
            ``(4) Agency contributions.--In addition to any funds made 
        available under section 402A(a)(3), the Secretary may transfer 
        funds from other departmental agencies and programs to carry 
        out the Initiative established under section 499B, including 
        the grant program established under this section, provided such 
        funds do not supplant funding under such section and such 
        transfer will further the authorized programs of the 
        contributing agency or program.''.

SEC. 103. CURES IN CARE INITIATIVE COLLABORATIVE.

    Part J of title IV of the Public Health Service Act (42 U.S.C. 290c 
et seq.) is amended by adding at the end the following:

``SEC. 499D. CURES IN CARE INITIATIVE COLLABORATIVE.

    ``(a) In General.--The Secretary, acting through the Director of 
NIH and the Director of the Center for Clinical Trial Innovation, shall 
establish, through entering into a contract, cooperative agreement, 
memorandum of understanding, or other mechanism, a public-private 
partnership, to be known as the Cures in Care Initiative Collaborative 
(in this section referred to as the `Collaborative'), to--
            ``(1) promote routine point-of-care clinical trials, 
        including the development of novel trial methodologies;
            ``(2) promote the elimination of barriers to trial 
        initiation and completion; and
            ``(3) support lead networks under the Cures in Care 
        Initiative established under section 499B.
    ``(b) Required Activities.--The Collaborative shall--
            ``(1) establish user groups, workshops, and other forums 
        for sponsors, contract research organizations, health care 
        organizations, technology providers, patient organizations, and 
        Federal agencies to identify and address implementation 
        barriers to routine point-of-care clinical trials;
            ``(2) provide technical assistance, including on protocol 
        development, regulatory interactions, and data infrastructure, 
        to sponsors of routine point-of-care clinical trials and lead 
        networks that receive a grant, or enter into a cooperative 
        agreement, contract, or other transaction, under section 499C;
            ``(3) support sandbox testing of innovations in trial 
        design, data infrastructure, consent, and governance prior to 
        broader adoption of such innovations;
            ``(4) evaluate incentives to support and sustain site 
        participation in clinical trial networks;
            ``(5) maintain public reporting on progress, barriers, and 
        outcomes of routine point-of-care clinical trial innovation;
            ``(6) coordinate with--
                    ``(A) existing public-private partnerships on 
                routine point-of-care clinical trial innovation;
                    ``(B) existing research infrastructures within the 
                National Institutes of Health and the Advanced Research 
                Projects Agency-Health; and
                    ``(C) the Center for Medicare and Medicaid 
                Innovation established under section 1115A of the 
                Social Security Act (42 U.S.C. 1315a), except that the 
                Collaborative may not direct, or be directed by, such 
                Center;
            ``(7) carry out the evaluation required under section 
        499C(d);
            ``(8) support practical technology and operational 
        enablement of lead networks, including development and testing 
        of integrated technology packages that can provide 
        participating sites with interoperable tools, standardized 
        workflows, training, implementation support, monitoring and 
        data quality capabilities, and centralized technical assistance 
        for less resourced sites; and
            ``(9) assess opportunities to centralize services, 
        including patient recruitment, to reduce the burden of 
        participation for clinical trial sites.
    ``(c) Federal Advisory Committee Act Applicability.--Chapter 10 of 
title 5, United States Code, shall not apply to the Collaborative.''.

SEC. 104. DEFINITIONS FOR CURES IN CARE INITIATIVE AND RELATED 
              ACTIVITIES.

    Part J of title IV of the Public Health Service Act (42 U.S.C. 290c 
et seq.) is amended by adding at the end the following:

``SEC. 499E. DEFINITIONS FOR CURES IN CARE INITIATIVE AND RELATED 
              ACTIVITIES.

    ``In this part:
            ``(1) Clinical investigation.--The term `clinical 
        investigation' has the meaning given such term in section 50.3 
        of title 21, Code of Federal Regulations (or any successor 
        regulation).
            ``(2) Innovative clinical trial method.--The term 
        `innovative clinical trial method' includes adaptive, 
        decentralized, Bayesian, platform, and external-control trial 
        designs, as such terms are described in guidance issued by the 
        Food and Drug Administration, including pursuant to section 
        3021 of the 21st Century Cures Act (21 U.S.C. 355 note) and 
        section 3606 of the Consolidated Appropriations Act, 2023 (21 
        U.S.C. 360a-1 note).
            ``(3) Lead disease or mechanism area.--The term `lead 
        disease or mechanism area' means a disease, condition, or 
        disease-mechanism area that presents substantial opportunity 
        for scaled, reusable platforms for routine point-of-care 
        clinical trials.
            ``(4) Lead network.--The term `lead network' means a 
        network of participating health care organizations for a lead 
        disease or mechanism area.
            ``(5) Less-resourced clinical trial setting.--The term 
        `less-resourced clinical trial setting' means a health care 
        organization or provider that--
                    ``(A) is located in, or primarily serves, a 
                medically underserved community (as defined in section 
                799B(6) of this Act); or
                    ``(B) is--
                            ``(i) a Federally qualified health center 
                        (as defined in section 1861 of the Social 
                        Security Act (42 U.S.C. 1395x));
                            ``(ii) a rural health clinic (as defined in 
                        such section);
                            ``(iii) a critical access hospital (as 
                        defined in such section);
                            ``(iv) a health center that, during the 
                        period in which such center is in a lead 
                        network established under section 499B(c) of 
                        this Act, receives a grant under section 330;
                            ``(v) a hospital that, during such period, 
                        receives a disproportionate share payment under 
                        section 1886(d)(5)(F) of the Social Security 
                        Act (42 U.S.C. 1395ww(d)(5)(F));
                            ``(vi) a facility owned or operated by the 
                        Indian Health Service;
                            ``(vii) a facility operated by an Indian 
                        Tribe, Tribal organization, or an urban Indian 
                        organization (as such terms are defined in 
                        section 4 of the Indian Health Care Improvement 
                        Act (25 U.S.C. 1603)); or
                            ``(viii) a health care provider that, 
                        during such period, receives a grant under 
                        title XXVI of the Public Health Service Act (42 
                        U.S.C. 300ff et seq.) (commonly known as the 
                        Ryan White HIV/AIDS program).
            ``(6) Routine point-of-care clinical trial.--The term 
        `routine point-of-care clinical trial' means a clinical 
        investigation of a medical product (as defined in section 499B 
        of this Act) that--
                    ``(A) is integrated into clinical practice, 
                including routine in-person or virtual visits;
                    ``(B) includes health providers as investigators;
                    ``(C) may be conducted in a primary care setting, 
                an outpatient care setting, the home of a patient 
                participating in such investigation, or a similar 
                location; and
                    ``(D) may follow a streamlined protocol and 
                procedures focused on essential data collection 
                generating or incorporating real-world data from an 
                electronic or other health record.''.

SEC. 105. DATA STANDARDS WITH RESPECT TO DATA SHARING.

    (a) In General.--Not later than 18 months after the date of 
enactment of this Act, the Administrator of the Centers for Medicare & 
Medicaid Services, the Commissioner of Food and Drugs, and the National 
Coordinator for Health Information Technology (in this section referred 
to as the ``Administrator'') shall establish a list of data standards 
for the purpose of facilitating the exchange of patient data for 
routine point-of-care clinical trials and contribution to Federal 
datasets using established common data models.
    (b) Required Contents.--In establishing the list under subsection 
(a), the Administrator shall include--
            (1) the United States Core Data for Interoperability;
            (2) the Fast Healthcare Interoperability Resources standard 
        maintained by Health Level Seven;
            (3) the Clinical Data Acquisition Standards Harmonization 
        maintained by the Clinical Data Interchange Standards 
        Consortium; and
            (4) the Study Data Tabulation Model maintained by such 
        Consortium.
    (c) Updates to List.--Not less than once every 3 years, the 
Administrator shall update the list of data standards established under 
subsection (a) to reflect new or successor standards adopted by the 
National Coordinator for Health Information Technology pursuant to 
section 3001 of the Public Health Service Act (42 U.S.C. 300jj-11).
    (d) Technical Specifications and Validation Pathways for Data 
Exchange.--Not later than 12 months after the date of enactment of this 
Act, the Administrator shall make available to the public on the 
website of the Department technical specifications and validation 
pathways by which data exchanged, in a manner consistent with the data 
standards included on the list established under subsection (a), may be 
translated for regulatory submission.
    (e) Privacy-Preserving Data Sharing.--The Administrator may 
implement data linkage and tokenization capabilities maintained by the 
Centers for Medicare & Medicaid Services to support data sharing in 
routine point-of-care clinical trials in compliance with--
            (1) the Health Insurance Portability and Accountability Act 
        of 1996 (Public Law 104-191);
            (2) section 552a of title 5, United States Code (commonly 
        referred to as the ``Privacy Act of 1974''); and
            (3) part 2 of title 42, Code of Federal Regulations (or any 
        successor regulation), relating to confidentiality of substance 
        use disorder patient records.
    (f) Implementation Plan.--Not later than 90 days after the date of 
enactment of this Act, the Administrator shall make available to the 
public on the website of the Department an implementation plan that--
            (1) includes milestones for carrying out each activity 
        under subsections (a) through (e);
            (2) designates lead officials at the Centers for Medicare & 
        Medicaid Services, the Food and Drug Administration, and the 
        Office of the National Coordinator for Health Information 
        Technology to carry out such activities;
            (3) describes how such activities align with the Cures in 
        Care Initiative established under section 499B of the Public 
        Health Service Act, as added by section 101 of this Act; and
            (4) describes how technology will be implemented in daily 
        clinical workflows, such as telehealth, remote monitoring, 
        eCOA/ePRO, wearables and connected devices, eConsent, EDC, 
        eSource, and EHR integration, with appropriate expectations for 
        validation, interoperability, data quality, privacy, 
        cybersecurity and regulatory use.
    (g) Amendment to FDA Guidance.--Not later than 12 months after the 
list of data standards is established under paragraph (1), the 
Commissioner of Food and Drugs shall update the guidance entitled 
``Real-World Data: Assessing Electronic Health Records and Medical 
Claims Data To Support Regulatory Decision-Making for Drug and 
Biological Products'' (89 Fed. Reg. 60430; issued July 25, 2024) (or 
successor guidance) to clarify how a person may use data shared in 
compliance with such standards when submitting an application seeking 
approval of a medical product, including for--
            (1) demonstrating the effectiveness of--
                    (A) medical products approved under section 506 or 
                515B of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 356; 21 U.S.C. 360e-3);
                    (B) a previously approved medical product for a new 
                indication of use; and
                    (C) a drug designated as an orphan drug under 
                section 526 of the Federal Food, Drug, and Cosmetic Act 
                (21 U.S.C. 360bb);
            (2) assessing fit-for-purpose validation of digital health 
        technologies and artificial intelligence tools that capture or 
        analyze such data for clinical investigations of medical 
        products; and
            (3) assessing how real-world evidence contained in Federal 
        datasets could be leveraged to support regulatory decision-
        making for medical product approval applications.

SEC. 106. CLINICAL TRIAL OVERSIGHT MODERNIZATION.

    (a) Single IRB Requirement for Certain Clinical Investigations.--
            (1) In general.--Subject to paragraph (2), a sponsor of 
        multi-institutional or cooperative clinical investigations of 
        medical products regulated under parts 45 and 56 of title 21, 
        Code of Federal Regulations (or any successor regulations), 
        shall designate a single institutional review board with 
        respect to the review of such investigation.
            (2) Exception.--If, in an investigational new drug 
        application or investigational device exemption application, 
        the sponsor described in paragraph (1) demonstrates that an 
        alternative manner of review is necessary and the designation 
        of only one institutional review board is not appropriate, such 
        sponsor may, with respect to a clinical investigation--
                    (A) rely on the review of an institutional review 
                board local to a site for such clinical investigation;
                    (B) enter into a joint review arrangement with 
                institutional review boards; or
                    (C) make such other arrangement to avoid a 
                duplication of effort.
            (3) Rulemaking.--Not later than 12 months after the date of 
        enactment of this Act, the Commissioner of Food and Drugs shall 
        issue such rules as may be necessary to implement this 
        subsection, including--
                    (A) amending parts 50 and 56 of title 21, Code of 
                Federal Regulations (or any successor regulation); and
                    (B) ensuring implementation of section 3023 of the 
                21st Century Cures Act (Public Law 114-255).
            (4) Definitions.--In this subsection:
                    (A) Investigational device exemption application.--
                The term ``investigational device exemption 
                application'' means an application submitted pursuant 
                to part 812 of title 21, Code of Federal Regulations 
                (or any successor regulation), to request an exemption 
                for an investigational device (as defined in section 
                812.3 of such part).
                    (B) Multi-institutional clinical investigation.--
                The term ``multi-institutional clinical investigation'' 
                means a clinical investigation conducted at not less 
                than two institutions under a single protocol.
    (b) IRB Transparency in Decision-Making.--Not later than 1 year 
after the date of enactment of this Act, the Secretary of Health and 
Human Services, acting through the Assistant Secretary of Health, 
Commissioner of Food and Drugs, and the Director of the National 
Institutes of Health shall issue such rules as may be necessary to 
amend title 21 and title 45, Code of Federal Regulations (and any 
successor regulations), to--
            (1) expand the public disclosure of Institutional Review 
        Board (referred to as ``IRB'' in this section) deliberations, 
        including summaries of key issues in submitted protocols and 
        summary bases of decisions;
            (2) maintain the confidentiality of protected health 
        information, commercial confidential data, and trade secrets in 
        such disclosures of IRB deliberations; and
            (3) implement such disclosures, to the extent practicable, 
        through the ClinicalTrials.gov website (or a successor website) 
        maintained by the National Library of Medicine.
    (c) Bioresearch Monitoring Capacity.--The Commissioner of Food and 
Drugs shall expand and enhance the bioresearch monitoring capacity of 
the Food and Drug Administration through the performance commitments 
under section 736B of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 379h-2).

SEC. 107. UPDATES TO PATIENT COSTS AND PAYMENT FOR PARTICIPATION IN 
              CLINICAL TRIALS.

    (a) Enabling Coverage of Patient Costs and Use of Evidence.--
            (1) Routine care cost coverage clarification.--
                    (A) In general.--Not later than 18 months after the 
                date of enactment of this Act, the Administrator of the 
                Centers for Medicare & Medicaid Services shall issue 
                guidance, or update the National Coverage Determination 
                for Routine Costs in Clinical Trials, to clarify that a 
                routine point-of-care clinical trial is a qualifying 
                clinical trial, such that coverage is available under 
                the Medicare program under title XVIII of the Social 
                Security Act (42 U.S.C. 1395 et seq.) for routine costs 
                incurred in connection with such trial, including items 
                and services furnished in connection with such trial 
                through digital health tools and through providers 
                operating in digital-first or remote care modalities.
                    (B) Alignments with data standards.--The 
                Administrator shall align the Centers for Medicare & 
                Medicaid Services quality measurement initiatives with 
                the data standards established under section 105.
            (2) Point-of-care evidence for coverage guidance.--Not 
        later than 18 months after the date of enactment of this Act, 
        the Administrator shall issue or update guidance on how 
        evidence from a routine point-of-care clinical trial may be 
        applied to--
                    (A) national coverage determinations (as defined in 
                section 1869(f)(1)(B) of the Social Security Act (42 
                U.S.C. 1395ff(f)(1)(B))) and updates thereto; and
                    (B) coverage of items and services subject to 
                conditions of evidence development established by the 
                Secretary under section 1862(a)(1)(A) of the Social 
                Security Act (42 U.S.C. 1395y(a)(1)(A)), commonly 
                referred to as coverage with evidence development.
    (b) Clinical Trial Participant Payment.--Not later than 1 year 
after the date of enactment of this Act, the Secretary, in consultation 
with the Commissioner of Food and Drugs and the Director of the Office 
of Human Research Protections shall issue such rules as may be 
necessary with respect to compensation for participants in a clinical 
trial as to ensure compensation is commensurate with the risks and 
burdens associated with the research and are not construed as 
constituting potential undue influence.
    (c) Clinical Trial Site Participant Payment.--Not later than 1 year 
after the date of enactment of this Act, the Secretary, in consultation 
with the Commissioner of Food and Drugs and the Director of the 
National Institutes of Health, shall issue such rules as may be 
necessary with respect to fair compensation for site participants in a 
clinical trial.

 TITLE II--MODERNIZED PRECLINICAL AND EARLY-STAGE CLINICAL DEVELOPMENT

SEC. 201. MODERNIZED EVIDENCE GENERATION THROUGH NEW APPROACH 
              METHODOLOGIES.

    (a) Guidance for Implementation of New Approach Methodologies.--
            (1) In general.--Not later than 2 years after the date of 
        enactment of this Act, the Secretary, acting through the 
        Commissioner of Food and Drugs (in this section referred to as 
        the ``Commissioner''), shall issue guidance and evidence 
        frameworks, including through amending existing guidance or 
        frameworks, to facilitate the implementation of new approach 
        methodologies for the purpose of streamlining and 
        accelerating--
                    (A) preclinical pharmacology and toxicology 
                studies;
                    (B) submission of investigational new drug 
                applications; and
                    (C) early clinical phases of drug development.
            (2) Contents.--In issuing guidance under paragraph (1), the 
        Commissioner shall--
                    (A) identify leading and novel use cases for in 
                vitro and in silico technology, including by--
                            (i) expanding on streamlined nonclinical 
                        programs and acceptable new approach 
                        methodologies;
                            (ii) describing additional opportunities to 
                        apply such technology to toxicology;
                            (iii) describing how to validate complex in 
                        vitro and in silico technology as new approach 
                        methodologies; and
                            (iv) describing the use of human-derived in 
                        vitro and ex vivo systems where a nonclinical 
                        species does not express, or does not 
                        adequately recapitulate binding to, the human 
                        target of a targeted biological product, 
                        including where a species-specific surrogate 
                        molecule would otherwise be required;
                    (B) implement pathways for the Center for Drug 
                Evaluation and Research and the Center for Biologics 
                Evaluation and Research to validate new approach 
                methodologies, for patients with a rare disease or 
                other serious and life-threatening conditions, 
                including the program established under section 507 of 
                the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
                357) and the plausible mechanism framework for rare 
                diseases implemented by the Food and Drug 
                Administration;
                    (C) incorporate--
                            (i) the information obtained through the 
                        workshops and meetings described in subsection 
                        (b); and
                            (ii) the policies established under 
                        subsection (c); and
                    (D) clarify the types and amount of data required 
                to validate a new approach methodology for a context of 
                use, and to expand such validated contexts of use.
    (b) Public Engagement.--The Commissioner, in consultation with the 
Director of the National Institutes of Health, shall hold workshops and 
public meetings to engage with sponsors, physicians, researchers, 
patients, and other stakeholders to, with respect to the development 
and validation of new approach methodologies, including in vitro and in 
silico technology--
            (1) encourage precompetitive collaboration between 
        sponsors, researchers, technology developers, and preclinical 
        research organizations;
            (2) identify incentives for sponsor participation, 
        including protection of intellectual property or such other 
        proprietary protection, to encourage data sharing from 
        completed preclinical projects; and
            (3) advance collaborative analyses and validations of such 
        methodologies to reduce development costs and increase the 
        acceptance of such methodologies for preclinical testing and 
        regulatory requirements, including by reducing or eliminating 
        animal testing for new medical products.
    (c) Regulatory Innovation.--The Commissioner, in consultation with 
the Director of the National Institutes of Health and the Director of 
the Advanced Research Projects Agency-Health shall, using the 
information obtained through the workshops and meetings described in 
subsection (b), establish a policy or platform for accelerated and 
precompetitive data sharing for, and analyses and validation of, new 
approach methodologies, that includes--
            (1) an incentive for sponsor participation, including a 
        method for regulatory validation of--
                    (A) digital and artificial intelligence tools;
                    (B) appropriate data security standards; and
                    (C) proprietary protection;
            (2) a novel or improved validation method for a new 
        approach methodology based on--
                    (A) data for such methodology; and
                    (B) traditional preclinical validation data for the 
                clinical investigation of a medical product, regardless 
                of whether such investigation proceeded to human 
                studies;
            (3) a sustainable method of funding, including--
                    (A) a sponsor applying to a Federal grant or 
                contract program;
                    (B) the Secretary establishing a Federal grant or 
                contract program; or
                    (C) the Secretary recommending that Congress--
                            (i) establish a new Federal grant or 
                        contract program for the purposes described in 
                        this section; or
                            (ii) take other legislative action to 
                        establish such method of funding; and
            (4) with respect to regulatory submissions, guidelines for 
        enhanced collaboration with international regulatory 
        authorities to advance the use and acceptance of a validated 
        new approach methodology.

SEC. 202. MODERNIZED PHASE 1 CLINICAL TRIAL OVERSIGHT.

    (a) In General.--The Secretary shall establish an expedited 
procedure for review and initiation of lower-risk phase 1 trials, 
including through--
            (1) issuing guidance, including through amending existing 
        guidance; and
            (2) establishing the pilot program under subsection (b).
    (b) Pilot Program.--
            (1) In general.--The Secretary shall establish a pilot 
        program for the third-party review of lower-risk phase 1 
        trials.
            (2) Qualified third parties.--
                    (A) Consideration as qualified third party.--A 
                third party is qualified to review a lower-risk phase 1 
                trial under the pilot program established under 
                paragraph (1) if such third party--
                            (i) is--
                                    (I) an institutional review board; 
                                or
                                    (II) such other third party, as 
                                determined by the Secretary;
                            (ii) has technical competency to--
                                    (I) review toxicology data; and
                                    (II) ensure Chemistry, 
                                Manufacturing, and Controls (in this 
                                section referred to as ``CMC'') data is 
                                compliant with good manufacturing 
                                practices in a manner that is 
                                commensurate with any review carried 
                                out by the Commissioner of Foods and 
                                Drugs with respect to investigational 
                                new drug applications; and
                            (iii) complies with the criteria 
                        established under subparagraph (B).
                    (B) Qualification criteria.--Using the criteria to 
                accredit or deny accreditation to persons who request 
                to perform the duties specified in section 523 of the 
                Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360m) 
                as a model, the Secretary shall establish criteria by 
                which a third party may be considered a qualified third 
                party under subparagraph (A)(iii).
            (3) Establishment of pilot program criteria.--In carrying 
        out the pilot program established under paragraph (1), the 
        Secretary shall establish criteria for a qualified third party 
        to review a lower-risk phase 1 trial, including the use of lead 
        use cases and compliance with best practices for the effective, 
        efficient, and timely ethical review and safety oversight of 
        such trial.
            (4) Enhanced oversight.--In carrying out the pilot program 
        established under paragraph (1), the Secretary shall--
                    (A) collect performance data with respect to such 
                pilot program;
                    (B) assess any review carried out under such pilot 
                program to ensure that the quality of such review is 
                commensurate with any review carried out by the 
                Commissioner of Foods and Drugs with respect to 
                investigational new drug applications; and
                    (C) audit any qualified third party who conducts 
                such a review to ensure program integrity.
            (5) Extension to higher-risk phase 1 trials.--The Secretary 
        shall assess--
                    (A) any information obtained under paragraph (4); 
                and
                    (B) the desirability of expanding such pilot 
                program to include the review of higher-risk phase 1 
                trials by--
                            (i) establishing and piloting pre-
                        certification standards with additional or 
                        enhanced requirements, as appropriate based on 
                        the risk of such trial, including for study 
                        conduct and monitoring, manufacturing, and 
                        adverse event mitigation;
                            (ii) developing specific guidance and pilot 
                        support for--
                                    (I) a qualified institutional 
                                review board to review such a trial for 
                                a cell or gene therapy, or a gene 
                                editing product;
                                    (II) clear and specific regulatory 
                                discussions for filing investigational 
                                new drug applications;
                                    (III) CMC-readiness by a sponsor or 
                                investigator of such a trial; and
                                    (IV) a dose escalation approach for 
                                such a trial; and
                            (iii) holding workshops, and publishing 
                        findings from such workshops, to support a 
                        potentially generalizable pre-certification 
                        process for early-stage studies of a cell or 
                        gene therapy, or a gene editing product.
            (6) Regulatory harmonization.--The Secretary shall assess 
        whether subpart A of part 46 of title 45, Code of Federal 
        Regulations (or any successor regulation), should be amended to 
        ensure regulatory consistency with any information obtained 
        under paragraphs (4) and (5).
    (c) Requirements With Respect to Establishing Expedited 
Procedure.--For purposes of carrying out this section, the Secretary 
shall--
            (1) establish criteria for classifying a phase 1 trial as a 
        lower-risk phase 1 trial or a higher-risk phase 1 trial;
            (2) assess relevant global regulatory programs with 
        decentralized and expedited review and approval of phase 1 
        trials, including the Clinical Trial Notification scheme 
        established by the Parliament of Australia in the Therapeutic 
        Goods Act 1989, and any amendments thereto; and
            (3) incorporate any findings from such assessment into the 
        expedited procedure established under subsection (a).
    (d) Appropriate Manufacturing Standards.--
            (1) Proposed rule.--Not later than 1 year after the date of 
        enactment of this Act, the Secretary shall issue a proposed 
        rule to revise such sections in title 21, Code of Federal 
        Regulations (or any successor regulations), relating to current 
        good manufacturing practices for drugs, as may be necessary to 
        ensure that, for an unapproved new drug or investigational drug 
        intended for use in a lower-risk phase 1 trial, the burden of 
        complying with CMC does not unnecessarily impede the initiation 
        of such trial.
            (2) Considerations.--In determining whether to revise a 
        regulation under paragraph (1), the Secretary shall consider--
                    (A) the criteria established under subsection 
                (c)(1);
                    (B) the risk associated with lower-risk phase 1 
                trials;
                    (C) the limited number of patients typically 
                enrolled in phase 1 trials;
                    (D) the use of small-batch, non-continuous 
                manufacturing processes;
                    (E) the clinical setting of lower-risk phase 1 
                trials, including--
                            (i) academic medical centers; or
                            (ii) in the case of routine point-of-care 
                        clinical trials, primary care and outpatient 
                        care settings; and
                    (F) the extent to which guidance for 
                investigational drugs intended for use in lower-risk 
                phase 1 trials can be included in regulation to provide 
                greater regulatory certainty.
            (3) Final rule.--Not later than 1 year after the date on 
        which the comment period ends for the proposed rule issued 
        under paragraph (1), the Secretary shall--
                    (A) incorporate any information obtained under 
                subsection (b)(4); and
                    (B) finalize such rule.
    (e) Definitions.--In this section:
            (1) Higher-risk phase 1 trial.--The term ``higher-risk 
        phase 1 trial'' means a phase 1 trial--
                    (A) of an investigational drug that is intended to 
                result in, or is capable of resulting in, modification 
                of the genome of a human cell, including by 
                integration, insertion, deletion, or base or prime 
                editing;
                    (B) of an investigational drug that is replication-
                competent or capable of horizontal transfer;
                    (C) of an investigational drug the biological 
                activity of which cannot be discontinued by cessation 
                of dosing;
                    (D) of an investigational drug intended to produce 
                sustained engagement of immune effector cells with an 
                antigen expressed on essential non-malignant human 
                tissue;
                    (E) of an investigational drug for which any prior 
                clinical investigation has been placed on clinical hold 
                pursuant to section 312.42 of title 21, Code of Federal 
                Regulations (or any successor regulation); or
                    (F) that is more likely to expose human subjects to 
                an unreasonable and significant risk of illness or 
                injury.
            (2) Lower-risk phase 1 trial.--The term ``lower-risk phase 
        1 trial'' means a phase 1 trial--
                    (A) that presents a minimal potential for harm to a 
                patient;
                    (B) that is an exploratory or phase 0 study of 
                subtherapeutic or non-toxic doses with no therapeutic 
                intent; or
                    (C) that is a study initiated by an investigator.
            (3) Phase 1 trial.--The term ``phase 1 trial'' means phase 
        1 of a clinical investigation of a previously untested drug, as 
        described in section 312.21 of title 21, Code of Federal 
        Regulations (or any successor regulation).

SEC. 203. GLOBAL REGULATORY ALIGNMENT TO MODERNIZE CLINICAL 
              DEVELOPMENT.

    (a) In General.--Section 803 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 383) is amended--
            (1) in subsection (b)--
                    (A) in paragraph (1), by striking ``, and'' and 
                inserting a semicolon;
                    (B) by redesignating paragraph (2) as paragraph 
                (4); and
                    (C) by adding after paragraph (1) the following:
            ``(2) the standard, entitled `Good Clinical Practice', 
        maintained by the International Council for Harmonisation;''; 
        and
            (2) by adding at the end the following:
    ``(d)(1) The Secretary shall expand and coordinate efforts, 
including through enhanced international collaboration, to ensure 
compliance with the standard, entitled `Good Clinical Practice', 
maintained by the International Council for Harmonisation for clinical 
trials conducted outside the United States.
    ``(2) The Secretary shall, in consultation with relevant nations 
and the International Council for Harmonisation, foster global 
regulatory alignment to modernize clinical early-stage medical product 
development, integrate real-world data and digital health information 
into clinical investigations, and ensure regulatory acceptance of 
investigations conducted by clinical trial networks embedded in routine 
practice.''.
    (b) Enhancing Data Integrity and Oversight of Clinical Trials at 
Sites of Concern.--Section 704 of the Federal Food, Drug, and Cosmetic 
Act (21 U.S.C. 374) is amended by adding at the end the following:
    ``(i)(1) With respect to an owner, operator, or agent in charge of 
an establishment carrying out a clinical investigation intended to 
support an application under section 505 of this Act or section 351 of 
the Public Health Service Act (42 U.S.C. 262), the Secretary shall, as 
part of the inspection of such establishment under this section--
            ``(A) require such owner, operator, or agent to pre-certify 
        that such clinical investigation complies with the standard, 
        entitled `Good Clinical Practice', maintained by the 
        International Council for Harmonisation; and
            ``(B) verify, on-site or remotely, that, prior to the 
        acceptance of data from any clinical trial site, contract 
        research organization, or data management vendor that meets the 
        criteria of a biotechnology company of concern (as defined in 
        section 851(f)(2) of the National Defense Authorization Act for 
        Fiscal Year 2026 (Public Law 119-60)), such clinical 
        investigation complies with--
                    ``(i) such standard; and
                    ``(ii) data security protocols.
    ``(2) The Secretary may require an owner, operator, or agent 
described in paragraph (1) to pay a fee to cover any cost related to 
the activities described in such paragraph.''.
    (c) Strengthening Foreign Early-Phase Data Verification.--
            (1) Documentation requirement.--The Secretary may, with 
        respect to any patient-level data from a phase 1 or phase 2 
        clinical investigation conducted outside of the United States, 
        require a sponsor or investigator to submit documentation of 
        such patient-level data for purposes of ensuring the integrity 
        of such investigation, such as--
                    (A) source data and audit trails for each primary 
                or secondary endpoint tested in such investigation;
                    (B) records of informed consent, translated into 
                English;
                    (C) the chain of custody for each biological sample 
                and test article used in such investigation; and
                    (D) other documentation as deemed necessary by the 
                Secretary.
            (2) Refusal of data.--The Secretary may refuse to accept 
        such patient-level data if a sponsor or investigator does not 
        comply with the requirement to provide documentation pursuant 
        to paragraph (1).
    (d) Guidance on Data Integrity and Inspection Access.--Not later 
than 18 months after the date of enactment of this Act, the Secretary 
shall revise the guidance issued by the Food and Drug Administration, 
entitled ``Guidance for Industry: Circumstances that Constitute 
Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection'', 
(issued June 2024) to provide clarification on any action the Secretary 
will take if a person does not comply with any requirement established 
by the Secretary under section 704(i) of the Federal Food, Drug, and 
Cosmetic Act, as added by subsection (b) of this section.

SEC. 204. MINIMUM UNITED STATES REPRESENTATION IN CLINICAL TRIALS.

    (a) In General.--The Secretary of Health and Human Services shall 
require that each pivotal study submitted in support of an application 
under section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355(b)) or section 351(a) of the Public Health Service Act (42 
U.S.C. 262(a)) meet the requirements of subsection (b).
    (b) U.S. Participation.--A pivotal study contained in an 
application under section 505(b) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355(b)) or section 351(a) of the Public Health 
Service Act (42 U.S.C. 262(a))--
            (1) may not be based solely on foreign clinical data;
            (2) shall include patients enrolled at clinical 
        investigation sites in the United States, including as part of 
        a multi-national clinical trial to support such application;
            (3) shall align with international harmonization efforts, 
        including the guidance issued by the International Council for 
        Harmonisation, entitled ``General Principles for Planning and 
        Design of Multi-Regional Clinical Trials'' (E17; adopted 
        November 16, 2017); and
            (4) shall include any other evaluation metrics as 
        determined by the Secretary, including if--
                    (A) the drug or biological product that is the 
                subject of the application described in this Act is 
                intended to treat a rare disease or condition;
                    (B) the Secretary determines that foreign clinical 
                data--
                            (i) is derived from a clinical 
                        investigation conducted in accordance with good 
                        clinical practice;
                            (ii) is applicable to the United States 
                        population and United States medical practice; 
                        and
                            (iii) is validated through an on-site 
                        inspection of the relevant trial site or other 
                        appropriate means, as determined by the 
                        Secretary;
                    (C) clinical investigation sites in the United 
                States are unavailable;
                    (D) establishing a clinical investigation site in 
                the United States is otherwise impracticable; or
                    (E) a waiver is necessary to protect public health 
                during a public health emergency.

SEC. 205. FOOD AND DRUG ADMINISTRATION RARE DISEASE INNOVATION HUB.

    The Federal Food, Drug, and Cosmetic Act is amended by adding after 
section 1014 (21 U.S.C. 360ff-1) the following:

``SEC. 1014A. FOOD AND DRUG ADMINISTRATION RARE DISEASE INNOVATION HUB.

    ``(a) Food and Drug Administration Rare Disease Innovation Hub.--
The Secretary shall establish the Food and Drug Administration Rare 
Disease Innovation Hub (in this section referred to as the `Hub') as an 
Intercenter Institute described in section 1014 to--
            ``(1) advance regulatory science for a rare disease or 
        condition;
            ``(2) provide technical assistance to review teams 
        assessing rare disease medical products to ensure reviewer 
        consistency and documentation of agreements upon acceptable 
        trial designs;
            ``(3) promote innovation of rare disease medical products;
            ``(4) leverage lead networks (established in title I of the 
        Faster Clinical Trials Act), interoperable technology and data 
        infrastructure, and public-private collaboration mechanisms to 
        advance natural history studies, distributed and platform 
        clinical trials, biomarker and clinical outcome assessment 
        development, and fit-for-purpose evidence generated from real-
        world data generation for rare diseases;
            ``(5) enhance coordination, alignment, and collaboration 
        between the heads of the Directors listed in subsection (b)(1) 
        and other Intercenter Institutes established under section 1014 
        with respect to the development and regulation of rare disease 
        medical products;
            ``(6) foster and support dialogue and public-private 
        partnerships with patients who have, and providers that treat, 
        a rare disease or condition to ensure such development is 
        patient-focused;
            ``(7) allow sponsors to consult with the Hub regarding 
        questions, concerns, or deliberations throughout the review 
        process; and
            ``(8) function as a point of escalation for sponsors of 
        rare disease medical products to request re-review or 
        consultation regarding review decisions.
    ``(b) Activities.--In addition to the activities of an Intercenter 
Institute described in section 1014, the Hub shall--
            ``(1) facilitate collaboration, information sharing, 
        regulatory consistency, and cross-disciplinary training and 
        product reviews with--
                    ``(A) the Office of Orphan Products Development;
                    ``(B) the Center for Drug Evaluation and Research;
                    ``(C) the Center for Biologics Evaluation and 
                Research;
                    ``(D) the Center for Devices and Radiological 
                Health; and
                    ``(E) the Oncology Center of Excellence; and
            ``(2) award grants, cooperative agreements, or contracts, 
        or enter into memoranda of understanding, to--
                    ``(A) support natural history studies, the use of 
                novel clinical trial designs, and the application of 
                the plausible mechanism evidentiary framework;
                    ``(B) accelerate the development and validation of 
                early and novel biomarkers and endpoints for rare 
                diseases or conditions, pursuant to section 507 of this 
                Act and section 3208 of the Food and Drug Omnibus 
                Reform Act (Public Law 117-328);
                    ``(C) ensure targeted technical assistance is 
                provided for--
                            ``(i) investigator-initiated clinical 
                        trials for medical products intended to treat 
                        rare diseases or conditions; and
                            ``(ii) patient-sponsored development 
                        programs for such medical products;
                    ``(D) hold meetings and workshops to engage 
                directly with--
                            ``(i) rare disease patient organizations 
                        and families of patients with rare diseases or 
                        conditions;
                            ``(ii) developers of rare disease medical 
                        products; and
                            ``(iii) researchers and specialty medical 
                        societies; and
                    ``(E) assist in addressing scientific, clinical, 
                and policy issues related to the development and 
                regulation of such products.
    ``(c) Public-Private Partnerships and Consortia.--The Hub shall 
foster public-private partnerships or consortia to support the 
activities required under this section, including initiatives to--
            ``(1) de-risk and facilitate access to manufacturing 
        capacity, including at Federal laboratories and facilities, 
        for--
                    ``(A) investigator-initiated clinical trials for 
                rare disease medical products; and
                    ``(B) patient-sponsored development programs for 
                such medical products; and
            ``(2) support clinical trials for, and development of, such 
        a medical product through a national network of clinical 
        centers of excellence for rare diseases or conditions.
    ``(d) Report.--Not later than 9 months after the date of enactment 
of this subsection, the Secretary shall submit to the Committee on 
Energy and Commerce of the House of Representatives and the Committee 
on Health, Education, Labor, and Pensions of the Senate, and make 
available to the public, a report containing recommendations on the 
development and regulation of a medical product intended to treat a 
rare disease or condition, including--
            ``(1) whether to selectively restore the establishment 
        license application under section 351 of the Public Health 
        Service Act (42 U.S.C. 262) to facilitate the manufacture of 
        rare disease medical products by nontraditional sponsors; and
            ``(2) whether to enhance regulatory flexibility and 
        manufacturing capacity for nontraditional sponsors, such as 
        academic laboratories or patient organizations, of--
                    ``(A) an investigator-initiated clinical trial for 
                a rare disease medical product;
                    ``(B) a patient-sponsored development program for 
                such a medical product; and
                    ``(C) research and development for medical products 
                intended to treat or diagnose very rare and n-of-1 
                diseases or conditions.
    ``(e) Funding.--
            ``(1) In general.--To carry out this section, the Secretary 
        shall transfer to the Hub for each of fiscal years 2027 through 
        2031--
                    ``(A) $5,000,000 from the amounts made available in 
                the FDA Innovation Account under section 1002(b)(2)(A) 
                of the 21st Century Cures Act (Public Law 114-255);
                    ``(B) $10,000,000 from the amounts made available 
                under section 481A of the Public Health Service Act (42 
                U.S.C. 287a-2) for clinical research into, training in, 
                and demonstration of diagnostic, prevention, control, 
                and treatment methods for rare diseases; and
                    ``(C) $15,000,000 from the amounts made available 
                to carry out section 499A(f) of such Act (42 U.S.C. 
                290c(f)), related to cooperation of the Advanced 
                Research Projects Agency-Health with the Food and Drug 
                Administration to facilitate the development of medical 
                products and projects that are the highest priorities 
                to the Advanced Research Projects Agency-Health.
            ``(2) Budget clarification.--Any budget request of the 
        President shall specify an amount for carrying out this 
        section.
    ``(f) Definitions.--In this section:
            ``(1) Medical product.--The term `medical product' means--
                    ``(A) a drug or device, as defined in section 201 
                of this Act; or
                    ``(B) a biological product, as defined in section 
                351 of the Public Health Service Act (42 U.S.C. 262).
            ``(2) Rare disease or condition.--The term `rare disease or 
        condition' has the meaning given such term in section 526.''.

TITLE III--ENHANCED FOOD AND DRUG ADMINISTRATION REGULATIONS TO SUPPORT 
                               INNOVATION

SEC. 301. RESOLVING CLINICAL HOLDS AND IMPROVING CLINICAL TRIAL 
              EFFICIENCY.

    (a) In General.--For purposes of improving the efficiency and 
integrity of clinical investigations, the Secretary shall address any 
root cause of a clinical hold imposed under section 312.42 of title 21, 
Code of Federal Regulations (or any successor regulation), or the 
disapproval or withdrawal of approval of an investigational device 
exemption under section 812.30 of such title (or any successor 
regulation), including--
            (1) identifying common sources of noncompliance with such 
        regulations and common causes of clinical holds and development 
        delays, with a focus on first-time sponsors of a clinical trial 
        and investigator-initiated clinical trials, IRBs, CROs and 
        other experienced implementation and technology partners, 
        research sites;
            (2) developing and disseminating best practices for--
                    (A) compliance with good clinical practices;
                    (B) efficient development, filing, and review of 
                investigational new drug applications and 
                investigational device exemptions; and
                    (C) increasing the frequency and documentation of 
                in-person meetings for sponsors of investigational new 
                drug applications and investigational device exemptions 
                in lieu of written responses to provide specific, 
                authoritative, and consistent guidance with a focus on 
                action items and enhancements;
            (3) early and additional sponsor engagement consistent 
        with, and additive to, the performance commitments under 
        section 736B of the Federal Food, Drug, and Cosmetic Act (21 
        U.S.C. 379h-2) to--
                    (A) secure rapid alignment on a trial design in 
                support of a complete application for a proposed 
                indication of use; and
                    (B) create additional opportunities for informal, 
                rapid feedback to such a sponsor, including science-
                focused drug development meetings;
            (4) increasing the use of external advisory committees;
            (5) early and consistent integration of staff with 
        requisite expertise in rare diseases or conditions, as 
        appropriate, in review teams for the review of investigational 
        and premarket new drug applications;
            (6) clarifying what information qualifies to be redacted 
        when disclosing complete response letters to the public;
            (7) revising procedures and guidance for--
                    (A) clarifying what information must be redacted 
                when publicly disclosing complete response letters and 
                other investigational and premarket new drug 
                application materials to the public;
                    (B) developing and publicly disclosing novel 
                redaction methods and tools, including automation or 
                artificial intelligence;
                    (C) the timely public disclosure of complete 
                response letters and other investigational and 
                premarket new drug application materials; and
                    (D) the establishment of pilot programs to 
                facilitate timely public access to such letters and 
                such application materials; and
            (8) creating a designated Food and Drug Administration 
        contact for process and regulatory-navigation questions for 
        emerging biotechnology companies.
    (b) Authorization of Appropriations.--There is authorized to be 
appropriated to carry out this section $500,000,000 for each of the 
fiscal years 2027 through 2031, to remain available until expended.

SEC. 302. MUTUAL RECOGNITION OF GMP STANDARDS.

    (a) Recognition of Foreign Government Inspections.--Section 809 of 
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 384e) is amended--
            (1) in subsection (a)--
                    (A) in paragraph (2), by striking ``and'' at the 
                end;
                    (B) in paragraph (3), by striking the period at the 
                end and inserting ``; and''; and
                    (C) by inserting after paragraph (3) the following:
            ``(4) shall implement a procedure for exchanging inspection 
        reports with a foreign government or an agency of a foreign 
        government that the Secretary has entered into an arrangement 
        or agreement with under this section to avoid duplicating an 
        inspection in which a foreign establishment registered under 
        section 510 was found to be in compliance with good 
        manufacturing practice regulations promulgated under section 
        501.'';
            (2) by redesignating subsection (c) as subsection (d);
            (3) by inserting after subsection (b) the following:
    ``(c) Risk-Based Prioritization Plan.--For purposes of increasing 
the rate of inspections, the Secretary shall implement a plan for the 
use of risk-based prioritization for inspections of establishments 
registered under section 510, which shall include consideration of--
            ``(1) the history of such an establishment with respect to 
        complying with good manufacturing practice regulations 
        promulgated under section 520(f);
            ``(2) the inherent risk of the drug or device manufactured, 
        prepared, propagated, compounded, or processed (as defined in 
        section 510) at such establishment; and
            ``(3) the availability of recent inspection reports from a 
        foreign government or an agency of a foreign government that 
        the Secretary has entered into an arrangement or agreement with 
        under this section.''; and
            (4) in paragraph (2) of subsection (d), as redesignated by 
        paragraph (2) of this section--
                    (A) by striking ``Beginning not later'' and 
                inserting the following:
                    ``(A) In general.--Beginning not later''; and
                    (B) by adding at the end the following:
                    ``(B) Reporting on mutual recognition.--The report 
                under subparagraph (A) shall include, with respect to 
                the period covered by the report an update on the 
                status of any agreement the Secretary enters into with 
                a foreign country under section 803 related to 
                encouraging the mutual recognition of good 
                manufacturing practice regulations promulgated under 
                section 520(f) with respect to inspections.''.
    (b) Expansion of Mutual Recognition Agreements to Bioresearch 
Monitoring.--Section 803(b) of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 383(b)) is amended by inserting after paragraph (2), as 
inserted by section 203(a)(1)(C), the following:
            ``(3) the bioresearch monitoring program implemented by the 
        Food and Drug Administration through compliance programs shall 
        identify ways to--
                    ``(A) allow such countries to rely on any 
                inspection conducted by the Food and Drug 
                Administration related to an establishment performing 
                clinical research;
                    ``(B) reduce the regulatory burden on such an 
                establishment in the United States; and
                    ``(C) provide the Secretary with maximum 
                flexibility to focus resources related to inspections 
                and compliance on establishments that pose the greatest 
                risk to data integrity or safety.''.

SEC. 303. PATHWAY FOR COMPETITIVE GENERIC THERAPIES.

    (a) Review.--The Secretary shall review and provide recommendations 
to improve the pathway for competitive generic therapies established 
pursuant to section 506H of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 356h) no later than 12 months after the date of the 
enactment of this Act.
    (b) Improvement.--Following the review under paragraph (1), the 
Secretary shall--
            (1) report the review, its findings, and any 
        recommendations to committees of jurisdiction within 12 months 
        of the date of the enactment of this Act; and
            (2) not later than 6 months after transmitting the review 
        to Congress, begin implementing the recommendations.
    (c) Collaboration.--In carrying out this section, the Secretary 
shall incorporate the perspectives of health care stakeholders.

SEC. 304. BIOSIMILAR BIOLOGICAL PRODUCTS.

    (a) In General.--Section 351(k) of the Public Health Service Act 
(42 U.S.C. 262(k)) is amended--
            (1) in the subsection heading, by striking ``or 
        Interchangeable'';
            (2) in paragraph (2)--
                    (A) by striking subparagraph (B);
                    (B) by redesignating clauses (ii) and (iii) of 
                subparagraph (A) as subparagraphs (B) and (C), 
                respectively, and adjusting the margins accordingly;
                    (C) in subparagraph (A)--
                            (i) in clause (i), by redesignating 
                        subclauses (I) through (V) as clauses (i) 
                        through (v), respectively, and adjusting the 
                        margins accordingly;
                            (ii) in clause (i), as so redesignated by 
                        clause (i) of this subparagraph, by 
                        redesignating items (aa) through (cc) as 
                        subclauses (I) through (III), respectively, and 
                        adjusting the margins accordingly;
                            (iii) in subclause (II) of clause (i), as 
                        so redesignated by clause (ii) of this 
                        subparagraph, by striking ``item (aa) or (cc)'' 
                        and inserting ``subclause (I) or (III)''; and
                            (iv) by striking ``(A) in general'' and all 
                        that follows through ``An application submitted 
                        under this subsection shall include 
                        information'' and inserting the following:
                    ``(A) In general.--An application submitted under 
                this subsection shall include information'';
                    (D) in subparagraph (B), as so redesignated by 
                subparagraph (B) of this paragraph, by striking 
                ``clause (i)(I)'' and inserting ``subparagraph 
                (A)(i)''; and
                    (E) in subparagraph (C), as so redesignated by 
                subparagraph (B) of this paragraph, by redesignating 
                subclauses (I) through (III) as clauses (i) through 
                (iii), respectively, and adjusting the margins 
                accordingly;
            (3) by amending subparagraph (A) of paragraph (3) to read 
        as follows:
                    ``(A) the Secretary determines that the information 
                submitted in the application (or the supplement) is 
                sufficient to show that the biological product is 
                biosimilar to the reference product; and'';
            (4) by amending paragraph (4) to read as follows:
            ``(4) Interchangeability.--
                    ``(A) In general.--A biological product licensed 
                under this subsection shall be deemed to be 
                interchangeable with the reference product, subject to 
                subparagraph (B).
                    ``(B) Timing of deemed interchangeability.--
                            ``(i) Licensure on or after transition 
                        date.--A biological product licensed under this 
                        subsection on or after the transition date 
                        described in subparagraph (C) (in this clause 
                        referred to as the `applicable biological 
                        product') shall be deemed to be interchangeable 
                        with the reference product upon such licensure, 
                        unless the applicable biological product relied 
                        on the same reference product as another 
                        biological product for which--
                                    ``(I) licensure under this 
                                subsection was in effect on the day 
                                before the date of enactment of the 
                                Faster Clinical Trials Act; and
                                    ``(II) a first interchangeable 
                                exclusivity period under paragraph (6) 
                                (as in effect on the day before the 
                                date of enactment of such Act) is in 
                                effect on the date of licensure of the 
                                applicable biological product,
                        in which case the applicable biological product 
                        shall be deemed interchangeable with the 
                        reference product under this paragraph on the 
                        date on which the exclusivity period described 
                        in subclause (II) ends.
                            ``(ii) Licensure prior to transition 
                        date.--A biological product licensed under this 
                        subsection prior to the transition date 
                        described in subparagraph (C) (referred to in 
                        this clause as the `applicable biological 
                        product') shall be deemed to be interchangeable 
                        with the reference product on such transition 
                        date, unless the applicable biological product 
                        relied on the same reference product as another 
                        biological product for which--
                                    ``(I) licensure under this 
                                subsection was in effect on the day 
                                before the date of enactment of the 
                                Faster Clinical Trials Act; and
                                    ``(II) a first interchangeable 
                                exclusivity period under paragraph (6) 
                                (as in effect on the day before the 
                                date of enactment of such Act) is in 
                                effect on the transition date,
                        in which case the applicable biological product 
                        shall be deemed interchangeable with the 
                        reference product under this paragraph on the 
                        date on which the exclusivity period described 
                        in subclause (II) ends.
                    ``(C) Transition date.--The transition date 
                described in this subparagraph is the date that is 60 
                days after the date of enactment of the Faster Clinical 
                Trials Act.'';
            (5) by amending paragraph (6) to read as follows:
            ``(6) Transition with respect to preserving first 
        interchangeable exclusivity with respect to certain biological 
        products.--With respect to a biological product licensed under 
        this subsection before the date of enactment of the Faster 
        Clinical Trials Act, for which there was an unexpired period of 
        first interchangeable exclusivity under this subsection (as 
        then in effect), such unexpired exclusivity period shall remain 
        in effect for the duration of such period.''; and
            (6) in paragraph (8)(D)--
                    (A) in clause (i), by striking ``class; and'' and 
                inserting ``class.'';
                    (B) by striking clause (ii); and
                    (C) by striking ``description of--'' and all that 
                follows through ``criteria that the Secretary'' and 
                inserting ``description of the criteria that the 
                Secretary''.
    (b) Conforming Amendments.--
            (1) Section 351(i)(3) of the Public Health Service Act (42 
        U.S.C. 262(i)(3)) is amended by striking ``that is shown to 
        meet the standards described in subsection (k)(4)'' and 
        inserting ``licensed under subsection (k)''.
            (2) Section 352A of the Public Health Service Act (42 
        U.S.C. 263-1) is amended by striking ``and interchangeable 
        biosimilar biological products'' each place such term appears.
            (3) Section 744G(14) of the Federal Food, Drug, and 
        Cosmetic Act (21 U.S.C. 379j-51(14)) is amended by striking ``, 
        including a supplement requesting that the Secretary determine 
        that the biosimilar biological product meets the standards for 
        interchangeability described in section 351(k)(4) of the Public 
        Health Service Act''.
            (4) Section 505B(l) of the Federal Food, Drug, and Cosmetic 
        Act (21 U.S.C. 355c(l)) is amended to read as follows:
    ``(l) Biosimilar Biological Products.--A biological product for 
which an application is submitted under section 351(k) of the Public 
Health Service Act shall be considered to have a new active ingredient 
for purposes of this section only if--
            ``(1) the application seeks licensure for a claimed 
        indication--
                    ``(A) that has been approved for a relevant 
                pediatric population; or
                    ``(B) for which there is a deferral of a relevant 
                pediatric assessment under subsection (a)(4) of this 
                section for the reference product applicant; and
            ``(2) a pediatric assessment under this section would not 
        involve the development of a biological product with a 
        strength, dosage form, route of administration, and condition 
        of use for which there would not be a reference product.''.
    (c) Guidance.--The Secretary shall--
            (1) not later than 18 months after the date of enactment of 
        this Act, update existing draft and final guidance to reflect 
        the amendments made by this section, including by revising or 
        revoking the guidance entitled ``Considerations in 
        Demonstrating Interchangeability With a Reference Product'' 
        (May 2019) and ``Considerations in Demonstrating 
        Interchangeability With a Reference Product: Update'' (June 
        2024);
            (2) not later than 18 months after the date of enactment of 
        this Act, issue or revise guidance on review and approval of 
        biosimilar biological products under section 351(k) of the 
        Public Health Service Act (42 U.S.C. 262(k)) relating to the 
        data and information that an applicant is required to submit to 
        support a determination that a biosimilar biological product 
        that is the subject of an application under such section is 
        biosimilar to the reference product (as defined in section 
        351(i) of such Act (42 U.S.C. 262(i))); and
            (3) not later than 18 months after the comment period 
        closes on the guidance under paragraphs (1) and (2), issue 
        revised draft or final versions of such guidance.
    (d) Rule of Construction.--The amendments made by this section 
shall not be construed--
            (1) to alter the standard or the information required for 
        licensure of a biological product as biosimilar to a reference 
        product pursuant to section 351(k) of the Public Health Service 
        Act (42 U.S.C. 262(k)); or
            (2) to limit the information that may be required by the 
        Secretary to support the licensure of a biological product as 
        biosimilar to a reference product pursuant to such section.

SEC. 305. CERTIFICATION OF PATENT INFORMATION IN CERTAIN APPLICATIONS 
              FOR BIOLOGICAL PRODUCTS.

    Section 351 of the Public Health Service Act (42 U.S.C. 262) is 
amended by adding at the end the following:
    ``(o) Certification of Patent Information in Certain 
Applications.--
            ``(1) In general.--An application submitted under this 
        section for a biological product that includes a full report of 
        a covered investigation shall also include--
                    ``(A) a certification, in the opinion of the 
                applicant and to the best of their knowledge, with 
                respect to each covered patent--
                            ``(i) that such patent information has not 
                        been filed;
                            ``(ii) that such patent has expired;
                            ``(iii) of the date on which such patent 
                        will expire; or
                            ``(iv) that such patent is invalid or will 
                        not be infringed by the manufacture, use, or 
                        sale of such product for which the application 
                        is submitted; and
                    ``(B) if information was filed under subsection (l) 
                for a method of use patent which does not claim a use 
                for which the applicant is seeking approval under this 
                section, a statement that the method of use patent does 
                not claim such a use.
            ``(2) Definitions.--In this subsection:
                    ``(A) Covered investigation.--The term `covered 
                investigation' means, with respect to a biological 
                product for which an applicant submitted an application 
                under this section, an investigation of such product 
                that--
                            ``(i) was conducted to demonstrate whether 
                        such product is safe for use and is effective 
                        in use;
                            ``(ii) was not conducted by or for the 
                        applicant and for which the applicant has not 
                        obtained a right of reference or use from the 
                        person by or for whom the investigation was 
                        conducted; and
                            ``(iii) is relied upon by the applicant 
                        seeking approval of such application.
                    ``(B) Covered patent.--The term `covered patent' 
                means a patent--
                            ``(i) which claims--
                                    ``(I) the biological product for 
                                which a covered investigation was 
                                conducted; or
                                    ``(II) a use for such product for 
                                which an applicant is seeking approval 
                                of an application under this section; 
                                and
                            ``(ii) for which information is required to 
                        be filed under subsection (l).''.

SEC. 306. GAO REPORT.

    Not later than 3 years after the date of enactment of this Act, the 
Comptroller General of the United States shall submit to Congress a 
report evaluating--
            (1) any progress in implementing section 301 during the 
        period covered by the report;
            (2) dissemination by the Food and Drug Administration of 
        resources related to developing a drug;
            (3) implementation by the Secretary of pilot programs using 
        fees made available pursuant to subchapter C of chapter VII of 
        the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379f et 
        seq.), such as the Split Real Time Application Review pilot 
        program, the Model-Informed Drug Development Paired Meeting 
        Program, and the Chemistry, Manufacturing, and Controls 
        Development and Readiness Pilot Program;
            (4) implementation by the Secretary of each program 
        established by this Act or an amendment made by this Act to 
        improve clinical trial efficiency and ensure regulatory 
        consistency; and
            (5) whether implementing each such program has had a 
        beneficial impact on the development of a medical product for a 
        rare disease or condition, including a rare cancer.

SEC. 307. DEFINITIONS.

    In this Act:
            (1) Clinical investigation.--The term ``clinical 
        investigation'' has the meaning given such term in section 50.3 
        of title 21, Code of Federal Regulations (or any successor 
        regulation).
            (2) Department.--The term ``Department'' means the 
        Department of Health and Human Services.
            (3) Good clinical practice.--The term ``good clinical 
        practice'' means the standard, entitled ``Good Clinical 
        Practice'', maintained by the International Council for 
        Harmonisation and implemented by the Secretary.
            (4) Institutional review board.--The term ``institutional 
        review board'' has the meaning given such term in section 
        56.102 of title 21, Code of Federal Regulations (or any 
        successor regulation).
            (5) Investigational new drug application.--The term 
        ``investigational new drug application'' means an application 
        submitted pursuant to part 312 of title 21, Code of Federal 
        Regulations (or any successor regulation), for an 
        investigational new drug (as defined in section 312.3 of such 
        part).
            (6) Medical product.--The term ``medical product'' means--
                    (A) a drug or device, as defined in section 201 of 
                the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
                321); or
                    (B) a biological product, as defined in section 351 
                of the Public Health Service Act (42 U.S.C. 262).
            (7) Rare disease or condition.--The term ``rare disease or 
        condition'' has the meaning given such term in section 526(a) 
        of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
        360bb(a)).
            (8) Routine point-of-care clinical trial.--The term 
        ``routine point-of-care clinical trial'' means a clinical 
        investigation of a medical product that--
                    (A) is integrated into clinical practice, including 
                routine in-person, or virtual, visits;
                    (B) includes health providers as investigators;
                    (C) may be conducted in a primary care setting, an 
                outpatient care setting, the home of a patient 
                participating in such investigation, or a similar 
                location; and
                    (D) may follow a streamlined protocol and 
                procedures focused on essential data collection 
                generating or incorporating real-world data from an 
                electronic or other health record.
            (9) Secretary.--The term ``Secretary'' means the Secretary 
        of Health and Human Services.

               TITLE IV--PRECISION ONCOLOGY MODERNIZATION

SEC. 401. FINDINGS AND PURPOSE.

    (a) Findings.--Congress finds the following:
            (1) Advances in molecular oncology have enabled the 
        identification of specific genetic alterations that drive 
        certain cancers, enabling the development of targeted therapies 
        with high efficacy in defined patient populations.
            (2) Approved oncology drug labels frequently reflect 
        clinical trial populations that predate the routine use of 
        genomic profiling and may not adequately reflect current 
        scientific understanding of patient subpopulations for whom a 
        given therapy is inappropriate.
            (3) Outdated labeling can contribute to suboptimal 
        treatment sequencing, unnecessary toxicity, and foregone 
        opportunity for patients to receive a more precisely and 
        effective targeted treatment option.
            (4) The Food and Drug Administration's Project Renewal 
        initiative, established to modernize drug product labeling to 
        reflect contemporary scientific and clinical knowledge, 
        provides a foundation that can be expanded to systematically 
        address genomic exclusions in oncology drug labels.
            (5) A formal, science-driven process for incorporating 
        genomic exclusion criteria into oncology labeling would promote 
        precision medicine, improve patient outcomes, and advance the 
        efficient use of health care resources.
    (b) Purpose.--To establish a process for reviewing and updating the 
labeling of approved oncology drugs to reflect genetically defined 
patient subpopulations.

SEC. 402. ONCOLOGY CENTER OF EXCELLENCE.

    (a) In General.--The Secretary shall establish the Food and Drug 
Administration Oncology Center of Excellence as an Intercenter 
Institute described in section 1014 to promote development and 
facilitate the review of medical products intended to diagnose and 
treat oncologic and hematologic malignancies, including--
            (1) cancers in infants, children, and adolescents; and
            (2) rare cancers.
    (b) Activities.--In addition to the activities of an Intercenter 
Institute described in section 1014, the Oncology Center of Excellence 
shall--
            (1) sponsor or conduct projects to advance the development 
        and regulation of medical products for patients with cancer, 
        including--
                    (A) Project Orbis a collaborative framework to 
                facilitate the concurrent submission and collaborative 
                regulatory review of oncology products among 
                international regulatory authorities to expedite global 
                patient access to safe and effective cancer treatments;
                    (B) Project Optimus a program to reform dose 
                optimization and selection for oncologic therapies by 
                encouraging multi-dose characterization early in 
                clinical development;
                    (C) Real-Time Oncology Review (RTOR) a voluntary 
                pilot program for the early submission of data modules 
                prior to the formal filing of a complete oncology 
                marketing application to streamline regulatory review;
                    (D) Project Confirm a public framework for the 
                monitoring of confirmatory clinical trials required 
                under the accelerated approval pathway for oncology 
                indications to track the confirmation of clinical 
                benefit;
                    (E) Project Pragmatica a program to integrate 
                pragmatic clinical trial designs into the evaluation of 
                approved oncology medical products, utilizing 
                streamlined eligibility criteria and real-world 
                clinical practice settings to reduce operational 
                burdens on patients and investigators; and
                    (F) Project Renewal a program to assess information 
                that may inform updates to the labeling of oncology 
                drugs to incorporate genomic exclusion criteria;
            (2) assist in addressing scientific, clinical, and policy 
        issues related to the development and regulation of oncology 
        and hematology products;
            (3) award grants, cooperative agreements, or contracts, or 
        enter into memoranda of understanding, and foster public-
        private partnerships or consortia to support the activities 
        required under this section; and
            (4) hold meetings and workshops to engage directly with--
                    (A) cancer patient organizations and families of 
                patients with cancer;
                    (B) developers of oncology and hematology products; 
                and
                    (C) researchers and specialty medical societies.
    (c) Funding.--
            (1) In general.--To carry out this section, the Secretary 
        shall transfer to the Oncology Center of Excellence for each of 
        fiscal years 2027 through 2031--
                    (A) such sums as necessary from the amounts made 
                available in the FDA Innovation Account under section 
                1002(b)(2)(A) of the 21st Century Cures Act (Public Law 
                114-255);
                    (B) such sums as necessary from amounts made 
                available pursuant to interagency transfers and 
                agreements, including with the National Cancer 
                Institute, as authorized under 31 U.S.C. 1535; and
                    (C) such sums as necessary from the amounts made 
                available to carry out section 499A(f) of such Act (42 
                U.S.C. 290c(f)), related to cooperation of the Advanced 
                Research Projects Agency-Health with the Food and Drug 
                Administration to facilitate the development of medical 
                products and projects that are the highest priorities 
                to the Advanced Research Projects Agency-Health.
            (2) Budget clarification.--Any budget request of the 
        President shall specify an amount for carrying out this 
        section.

SEC. 403. LABELING REVISIONS FOR GENOMIC EXCLUSIONS IN ONCOLOGY DRUGS.

    (a) In General.--Not later than 12 months after the date of 
enactment of this Act, the Secretary shall establish, acting through 
the Food and Drug Administration Oncology Center of Excellence 
(hereinafter referred to as the ``Center''), a program to assess 
information that may inform updates to the labeling of approved 
oncology drugs to incorporate genomic exclusion criteria (hereinafter 
referred to as the ``Program'').
    (b) Duties.--In carrying out the Program, the Center shall--
            (1) identify oncology drugs approved under 505(b) or 505(j) 
        of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b) 
        or (j)), or licensed under section 351 of the Public Health 
        Service Act (42 U.S.C. 262) for which--
                    (A) there is new scientific evidence available 
                pertaining to one or more actionable genetic 
                alterations that is not reflected in the approved 
                labeling of such drugs; and
                    (B) the updating of such approved labeling would 
                benefit the public health; and
            (2) establish a process to--
                    (A) identify such drugs, including--
                            (i) the procedures authorized under section 
                        503D(b) of the Federal Food, Drug, and Cosmetic 
                        Act (21 U.S.C. 353d(b)), to receive clinical 
                        evidence on the impact of actionable genetic 
                        alterations on patient outcomes; and
                            (ii) engagement through meetings and 
                        workshops authorized under section 3(b)(4) 
                        with--
                                    (I) holders of approved oncology 
                                drug applications and other drug 
                                sponsors;
                                    (II) the Food and Drug 
                                Administation Rare Disease Innovation 
                                Hub;
                                    (III) the National Cancer 
                                Institute; and
                                    (IV) patient advocacy 
                                organizations, oncology professional 
                                societies, diagnostic test developers, 
                                and other relevant stakeholders;
                    (B) develop standardized language for genomic 
                exclusion criteria to support clear statements 
                regarding the additional, modified, or supplemental 
                information for amended oncology drug labeling;
                    (C) encourage holders of approved oncology drug 
                applications to submit voluntary labeling supplements 
                to incorporate genomic exclusion criteria, including as 
                supplemental applications described in sections 314.70 
                and 601.12 of title 21, Code of Federal Regulations (or 
                any successor regulations); and
                    (D) initiate labeling changes to incorporate 
                genomic exclusion criteria, including under section 
                505(o) of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355(o)) and in a manner consistent with the 
                requirements of section 503D(f)(2) of the Federal Food, 
                Drug, and Cosmetic Act (21 U.S.C. 353D(f)(2)).
    (c) Selection of Oncology Drugs.--The Center shall identify 
oncology drugs under this section--
            (1) based on factors including--
                    (A) the strength and consistency of clinical 
                evidence supporting the impact of the action genetic 
                alteration on patient outcomes;
                    (B) the availability of one or more approved 
                targeted oncology therapies addressing the relevant 
                actionable genetic alteration or oncogenic driver;
                    (C) the prevalence of the relevant genetic 
                alteration or oncogenic driver in the indicated patient 
                population; and
                    (D) the potential clinical impact of failing to 
                identify and exclude patients with the relevant 
                alteration;
            (2) on the basis of the available scientific evidence for 
        incorporating genomic exclusion criteria into oncology drug 
        labeling that meets the standards under section 505 for adding 
        or modifying information to the labeling or providing 
        supplemental information to the labeling regarding the use of 
        the identified drug, including--
                    (A) data from randomized controlled trials 
                demonstrating reduced effectiveness or safety changes 
                of approved oncology products for patients with 
                specific actionable genetic alterations;
                    (B) prospective or retrospective biomarker analyses 
                from adequate and well-controlled studies;
                    (C) real-world evidence; and
                    (D) mechanistic or preclinical evidence in 
                conjunction with clinical data, where appropriate; and
            (3) with consideration given to--
                    (A) whether a companion diagnostic test approved or 
                cleared under section 515 or section 510(k) of the 
                Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360e 
                and 21 U.S.C. 360(k)) respectively, or a laboratory 
                developed test, is necessary to identify patients with 
                a relevant actionable genetic alteration prior to 
                seeking or initiating a labeling change to incorporate 
                a genomic exclusion criterion into labeling under 
                subsection (b);
                    (B) promoting alignment, in coordination with the 
                Center for Devices and Radiological Health, as 
                appropriate, between revised oncology drug labeling 
                under this section and the labeling of approved or 
                cleared companion diagnostics; and
                    (C) utilization of genomic profiling under next-
                generation sequencing or other multi-gene testing as a 
                basis for identifying patients subject to a genomic 
                exclusion criterion.
    (d) Expedited Review for Labeling Supplements.--Labeling 
supplements to incorporate genomic exclusion criteria submitted 
pursuant to 505(xx) or 505(o)(4) shall--
            (1) be exempt from user fees under the Prescription Drug 
        User Fee Act; and
            (2) be reviewed and acted upon no later than 180 days after 
        submission of a complete supplement.
Nothing in this subsection shall be constructed to limit the processes 
outlined in 505(o)(4).
    (e) Transparency and Public Access.--The Secretary shall--
            (1) maintain and make publicly available on the Food and 
        Drug Administration's website a registry of oncology drug 
        labels updated under the Program, and the evidence basis for 
        each genomic exclusion determination; and
            (2) publish, not less frequently than annually, a report 
        summarizing Program activities, labeling updates completed, 
        supplements received and acted upon, and any anticipated 
        genetic alterations under consideration for the following year;
    (f) Guidance.--Within 180 days of enactment of the Precision 
Oncology Modernization Act, the Secretary shall issue draft guidance on 
the actions described in subsection (b), standards in subsection (c), 
and role of the CDRH outlined in subsection (d). The guidance shall be 
finalized no later than 2 years after enactment.
    (g) Report to Congress.--Not later than 3 years after the date of 
enactment of this Act, and every 2 years thereafter, the Secretary 
shall submit to the Committee on Energy and Commerce of the House of 
Representatives and the Committee on Health, Education, Labor, and 
Pensions of the Senate a report that includes--
            (1) a description of the activities carried out under the 
        Program, including the number of oncology drug labels reviewed, 
        updated, or pending update;
            (2) the number of voluntary labeling supplements received 
        and acted upon under the Program;
            (3) an assessment of challenges and barriers encountered in 
        implementing the Program, including any scientific, legal, or 
        operational barriers;
            (4) recommendations for legislative or regulatory changes 
        that would improve the Program or accelerate the incorporation 
        of genomic exclusion criteria into oncology drug labeling; and
            (5) an analysis of the potential impact of Program 
        activities on patient outcomes, treatment sequencing, and 
        access to targeted oncology therapies.
    (h) Rule of Construction.--Nothing in this Act shall be construed--
            (1) to limit the authority of the Secretary to require 
        labeling changes for approved drugs under any other provision 
        of the Federal Food, Drug, and Cosmetic Act or the Public 
        Health Service Act; and
            (2) to affect the approval status of any oncology drug or 
        biological product approved before the date of enactment of 
        this Act except with respect to labeling updates made pursuant 
        to the Program.
The rules of construction under section 503D(i) of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 353d(b)) shall be deemed to apply to 
this section.
    (i) Definitions.--In this Act:
            (1) Actionable genetic alteration.--The term ``actionable 
        genetic alteration'' means a somatic or germline mutation, gene 
        fusion, copy number variation, or other molecular aberration in 
        a patient's tumor or germline that has been demonstrated 
        through clinical evidence to predict a meaningful difference in 
        response or resistance that impacts the safety or efficacy of a 
        drug or biological product intended to treat cancer.
            (2) Approved targeted oncology therapy.--The term 
        ``approved targeted oncology therapy'' means a drug or 
        biological product approved under section 505 of the Federal 
        Food, Drug, and Cosmetic Act (21 U.S.C. 355) or section 351 of 
        the Public Health Service Act (42 U.S.C. 262) for the treatment 
        of a cancer defined in whole or in part by the presence of a 
        specific genetic alteration.
            (3) Genomic exclusion criterion.--The term ``genomic 
        exclusion criterion'' means a labeling statement specifying 
        that a drug is not indicated for, or should not be used in, 
        patients whose tumors harbor a specific actionable genetic 
        alteration for which an alternative approved targeted oncology 
        therapy exists.

                   TITLE V--AMERICAN FRONTIER BIOBANK

SEC. 501. ESTABLISHMENT OF THE AMERICAN FRONTIER BIOBANK.

    (a) In General.--Part A of title IV of the Public Health Service 
Act (42 U.S.C. 281et seq.) is amended by adding at the end following:

``SEC. 404P. AMERICAN FRONTIER BIOBANK.

    ``(a) In General.--Pursuant to section 498E, the Director of NIH 
shall carry out a program to be known as the `American Frontier Biobank 
Program' (referred to in this section as the `Biobank Program'), which 
shall expand upon the work of the All of Us Research Program.
    ``(b) Transition.--Not later than 6 months after the date of the 
enactment of this section, the Director of NIH shall--
            ``(1) transfer to the Biobank Program, the authorities 
        (including all budget authorities, available appropriations, 
        and personnel), duties, obligations, and related legal and 
        administrative functions, and the existing cohort, data, 
        computational infrastructure, and biobanking capabilities of 
        the All of Us Research Program; and
            ``(2) provide for the orderly transition or realignment of 
        awards made under, and capabilities of, the All of Us Research 
        Program.
    ``(c) Administrator.--The Biobank Program shall be headed by an 
Administrator appointed by the Director of NIH. Such person shall be 
known and referred to as the American Frontier Biobank Administrator 
(in this section referred to as the `Administrator').
    ``(d) Program Elements.--In carrying out the Biobank Program, the 
Administrator shall--
            ``(1) make awards to, or enter into contracts with, 
        corporate entities or nonprofit entities across the United 
        States to facilitate--
                    ``(A) the collection, storage, molecular data 
                generation, and analysis of biological specimens, 
                including longitudinal molecular and clinical data; and
                    ``(B) with the support of artificial intelligence 
                and other technologies, as appropriate, incorporating 
                electronic health records of participants in accordance 
                with subsection (c);
            ``(2) facilitate the recruitment of participants that are 
        representative of at least 3 percent of the United States 
        population, including representation of each State of the 
        United States, the District of Columbia, each commonwealth, 
        territory or possession of the United States, and each 
        federally recognized Indian Tribe, with longitudinal data 
        gathered in both urban and rural populations, including a 
        pediatric cohort of participants;
            ``(3) in facilitating the recruitment of participants under 
        paragraph (2) who are members of a federally recognized Indian 
        Tribe, work in partnership with Tribal nations, and through 
        Tribal consultation, to establish mutually agreeable terms for 
        Tribal participation, and operational processes and oversight, 
        that respect Tribal sovereignty;
            ``(4) enter into data sharing agreements with private and 
        nonprofit entities to build upon existing processes for the 
        rapid, cost-effective, and scalable recruitment, and enrollment 
        of, and obtaining informed consent from, participants for the 
        collection of longitudinal data;
            ``(5) seek to enroll in clinical trials, using data in the 
        Biobank, the individuals whose biological specimens are stored 
        in the Biobank;
            ``(6) share deidentified data collected for the Biobank 
        Program with all registered researchers;
            ``(7) incorporate existing data sources of the National 
        Institutes of Health, and other relevant datasets (as 
        determined by the Administrator) into research activities 
        conducted through the Biobank Program, including data collected 
        through the All of Us initiative and the Department of Veterans 
        Affairs Millions Veterans Program;
            ``(8) generate and integrate multi-modal data, including 
        genomic, proteomic, metabolomic, and other molecular data, with 
        electronic health records and participant-reported information;
            ``(9) enable longitudinal participant data collection, 
        including by conducting repeat sampling, engaging in continuous 
        health data integration, and developing scalable research 
        infrastructure to reduce the long-term costs of biomedical 
        research and health care innovation;
            ``(10) support artificial intelligence-ready 
        infrastructure, including secure, federated data systems that 
        enable large-scale analysis while deidentifying patient data;
            ``(11) facilitate the translation of research findings into 
        clinical applications, including mechanisms for public and 
        private funding to support Biobank Program activities; and
            ``(12) carry out all other activities as determined by the 
        advisory board for the Biobank.
    ``(e) Advisory Board.--The Director of NIH shall establish a 
national advisory board to oversee the functions of the Biobank. The 
advisory board shall include representatives from--
            ``(1) the Institutes and Centers of the National Institutes 
        of Health;
            ``(2) other relevant Federal agencies;
            ``(3) public and private research institutions, including 
        entities that performed key participant and community 
        engagement, genomic sequencing, and data security functions of 
        the All of Us Research Program;
            ``(4) health care systems;
            ``(5) artificial intelligence and data experts;
            ``(6) clinical trial design experts;
            ``(7) pharmaceutical, biologic, and medical technology 
        companies; and
            ``(8) experts in the ethical, legal, and social 
        implications of science and technology.
    ``(f) Multi-Modal Data.--The data described in subsection (c)(7) 
may link biological, clinical, environmental, and other data, including 
information related to environmental exposures and factors identified 
using a life course approach.
    ``(g) Privacy Protections and Informed Consent.--
            ``(1) In general.--The Director of NIH shall ensure that 
        any entity collecting data or specimens from any individual 
        through the Biobank Program or conducting any clinical trial 
        using such data or specimens, or in any other way using such 
        data or specimens--
                    ``(A) collects biospecimens and associated clinical 
                and demographic information only from participants who 
                have given their informed consent in accordance with 
                Federal and State law; and
                    ``(B) protects personal privacy to the extent 
                required by applicable Federal and State law, at 
                minimum.
            ``(2) Informed consent.--The Director of NIH shall continue 
        to ensure that all biospecimens and associated clinical and 
        other demographic information are collected with the informed 
        consent and authorization of individuals participating in the 
        Biobank Program, or their legally authorized representative, in 
        accordance with the law.
    ``(h) Congressional Notification.--Not later than one year after 
the date of the enactment of this section, and annually thereafter, the 
Director of NIH shall submit to the appropriate congressional 
committees a notification on all activities as determined by the 
advisory board for the Biobank.
    ``(i) Authorization of Appropriations.--For purposes of carrying 
out this section, there is authorized to be appropriated $500,000,000 
for fiscal year 2027 and each subsequent fiscal year, to remain 
available until expended.''.
    (b) Roadmap.--Not later than 180 days after the date of the 
enactment of this Act, the Director of NIH shall submit to Congress, in 
consultation with relevant public and private entities on the advisory 
board, a roadmap for implementation and augmentation of the Biobank 
Program established under section 404P of the Public Health Service 
Act, as added by subsection (a), including scientific priorities, an 
infrastructure development plan, a public-private partnership financing 
strategy, and a budget for 5 fiscal years.
                                 <all>
Suggest a tool

Suggest a tool

A person reads each idea before it appears. Links are not accepted. Do not include personal information.

See all ideas and vote